Pertussis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 96 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pertussis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pertussis - Pipeline Review, H2 2014', provides an overview of the Pertussis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pertussis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pertussis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pertussis Overview 10
Therapeutics Development 11
Pipeline Products for Pertussis - Overview 11
Pipeline Products for Pertussis - Comparative Analysis 12
Pertussis - Therapeutics under Development by Companies 13
Pertussis - Therapeutics under Investigation by Universities/Institutes 16
Pertussis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Pertussis - Products under Development by Companies 21
Pertussis - Products under Investigation by Universities/Institutes 23
Pertussis - Companies Involved in Therapeutics Development 24
Sanofi 24
GlaxoSmithKline plc 25
Daiichi Sankyo Company, Limited 26
Takeda Pharmaceutical Company Limited 27
Biological E. Limited 28
Novartis AG 29
Zydus Cadila Healthcare Limited 30
DBV Technologies SA 31
Green Cross Corporation 32
LG Life Sciences, Ltd. 33
Panacea Biotec Limited 34
Bharat Biotech International Limited 35
Sinovac Biotech Ltd. 36
NanoBio Corporation 37
Beijing Tiantan Biological Products Co., Ltd. 38
Synthetic Biologics, Inc. 39
Serum Institute of India Limited 40
Indian Immunologicals Limited 41
Beijing Minhai Biotechnology Co., Ltd 42
Sanofi Pasteur SA 43
Pertussis - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
diphtheria + tetanus toxoids + acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DtwP-HB-Hib (liq) Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis (inactivated) + haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DTwP-HBV-Hib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VN-0103 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GSK-217744 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TAK-361S - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus+ pertussis vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pertussis vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diphtheria + pertussis + tetanus vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
diphtheria + pertussis + tetanus vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine for Diptheria, Tetanus and Pertussis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SYN-005 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-3111A - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DTwP-IPV - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DTaP Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Diphtheria + Tetanus + Pertussis (Acellular) Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pertussis vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
DPT-H-HiB Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Pertussis Vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Pertussis Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Acellular Pertussis Vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Pertussis Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Pertussis (Acellular) Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
DTwP-Hep B-IPV-Hib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
DTwP-IPV + Hib - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
DTwP + Hib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Pertussis - Recent Pipeline Updates 85
Pertussis - Dormant Projects 87
Pertussis - Product Development Milestones 88
Featured News & Press Releases 88
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 88
Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 88
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 89
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 90
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 91
Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 92
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 93
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 93
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 93
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 94
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 96
Disclaimer 96

List of Tables
Number of Products under Development for Pertussis, H2 2014 11
Number of Products under Development for Pertussis - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2014 23
Pertussis - Pipeline by Sanofi, H2 2014 24
Pertussis - Pipeline by GlaxoSmithKline plc, H2 2014 25
Pertussis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 26
Pertussis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 27
Pertussis - Pipeline by Biological E. Limited, H2 2014 28
Pertussis - Pipeline by Novartis AG, H2 2014 29
Pertussis - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 30
Pertussis - Pipeline by DBV Technologies SA, H2 2014 31
Pertussis - Pipeline by Green Cross Corporation, H2 2014 32
Pertussis - Pipeline by LG Life Sciences, Ltd., H2 2014 33
Pertussis - Pipeline by Panacea Biotec Limited, H2 2014 34
Pertussis - Pipeline by Bharat Biotech International Limited, H2 2014 35
Pertussis - Pipeline by Sinovac Biotech Ltd., H2 2014 36
Pertussis - Pipeline by NanoBio Corporation, H2 2014 37
Pertussis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 38
Pertussis - Pipeline by Synthetic Biologics, Inc., H2 2014 39
Pertussis - Pipeline by Serum Institute of India Limited, H2 2014 40
Pertussis - Pipeline by Indian Immunologicals Limited, H2 2014 41
Pertussis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 42
Pertussis - Pipeline by Sanofi Pasteur SA, H2 2014 43
Assessment by Monotherapy Products, H2 2014 44
Assessment by Combination Products, H2 2014 45
Number of Products by Stage and Target, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Pertussis Therapeutics - Recent Pipeline Updates, H2 2014 85
Pertussis - Dormant Projects, H2 2014 87